Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Fernandez-gonzalez S, Falo C, Pla MJ, Pernas S, Bajen M, Soler T, Ortega R, Quetglas C, Perez-martin X, Fernandez Montoli ME, Campos M, Varela-rodriguez M, Ponce J, Garcia-tejedor A. The Shift From Sentinel Lymph Node Biopsy Performed Either Before or After Neoadjuvant Systemic Therapy in the Clinical Negative Nodes of Breast Cancer Patients. Results, and the Advantages and Disadvantages of Both Procedures. Clin Breast Cancer 2018;18:71-7. [DOI: 10.1016/j.clbc.2017.08.014] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2017] [Revised: 07/31/2017] [Accepted: 08/11/2017] [Indexed: 12/23/2022]

For:	Fernandez-gonzalez S, Falo C, Pla MJ, Pernas S, Bajen M, Soler T, Ortega R, Quetglas C, Perez-martin X, Fernandez Montoli ME, Campos M, Varela-rodriguez M, Ponce J, Garcia-tejedor A. The Shift From Sentinel Lymph Node Biopsy Performed Either Before or After Neoadjuvant Systemic Therapy in the Clinical Negative Nodes of Breast Cancer Patients. Results, and the Advantages and Disadvantages of Both Procedures. Clin Breast Cancer 2018;18:71-7. [DOI: 10.1016/j.clbc.2017.08.014] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2017] [Revised: 07/31/2017] [Accepted: 08/11/2017] [Indexed: 12/23/2022]

Number

Cited by Other Article(s)

Fernandez-Gonzalez S, Falo C, Pla MJ, Campos M, Ortega-Exposito C, Ortega R, Vicente M, Petit A, Bosch-Schips J, Bajen MT, Reyes G, Martínez E, González-Viguera J, Peñafiel J, Stradella A, Pernas S, Ponce J, Garcia-Tejedor A. Sentinel lymph node biopsy before and after neoadjuvant chemotherapy in cN0 breast cancer patients: impact on axillary morbidity and survival-a propensity score cohort study. Breast Cancer Res Treat 2024;206:131-141. [PMID: 38635082 PMCID: PMC11182812 DOI: 10.1007/s10549-024-07274-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2023] [Accepted: 01/30/2024] [Indexed: 04/19/2024]

Affiliation(s)

Sergi Fernandez-Gonzalez Department of Gynecology, Multidisciplinary Breast Cancer Unit, Hospital Universitari Bellvitge, Idibell, c/ Feixa Llarga s/n. Hospitalet de Llobregat, CP: 08907, Barcelona, Spain. Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Feixa Llarga, s/n, 08907, l'Hospitalet de Llobregat, Spain.
Catalina Falo Department of Medical Oncology, Multidisciplinary Breast Cancer Unit, Institut Català d'Oncologia, Idibell, Barcelona, Spain
Maria J Pla Department of Gynecology, Multidisciplinary Breast Cancer Unit, Hospital Universitari Bellvitge, Idibell, c/ Feixa Llarga s/n. Hospitalet de Llobregat, CP: 08907, Barcelona, Spain
Miriam Campos Department of Gynecology, Multidisciplinary Breast Cancer Unit, Hospital Universitari Bellvitge, Idibell, c/ Feixa Llarga s/n. Hospitalet de Llobregat, CP: 08907, Barcelona, Spain
Carlos Ortega-Exposito Department of Gynecology, Multidisciplinary Breast Cancer Unit, Hospital Universitari Bellvitge, Idibell, c/ Feixa Llarga s/n. Hospitalet de Llobregat, CP: 08907, Barcelona, Spain
Raul Ortega Department of Radiology, Multidisciplinary, Breast Cancer Unit. Hospital Universitari Bellvitge, Idibell, Barcelona, Spain
Maria Vicente Department of Radiology, Multidisciplinary, Breast Cancer Unit. Hospital Universitari Bellvitge, Idibell, Barcelona, Spain
Ana Petit Department of Pathology, Multidisciplinary Breast Cancer Unit, Hospital Universitari Bellvitge, Idibell, Barcelona, Spain
Jan Bosch-Schips Department of Pathology, Multidisciplinary Breast Cancer Unit, Hospital Universitari Bellvitge, Idibell, Barcelona, Spain
Maria Teresa Bajen Department of Nuclear Medicine, Multidisciplinary Breast Cancer Unit, Hospital Universitari Bellvitge, Idibell, Barcelona, Spain
Gabriel Reyes Department of Nuclear Medicine, Multidisciplinary Breast Cancer Unit, Hospital Universitari Bellvitge, Idibell, Barcelona, Spain
Evelyn Martínez Department of Radiation Oncology, Multidisciplinary Breast Cancer Unit, Institut Català d'Oncologia, Barcelona, Spain
Javier González-Viguera Department of Radiation Oncology, Multidisciplinary Breast Cancer Unit, Institut Català d'Oncologia, Barcelona, Spain
Judith Peñafiel Biostatistics Unit, Institut d'Investigació Biomèdica de Bellvitge, Hospitalet de Llobregat, Spain
Agostina Stradella Department of Medical Oncology, Multidisciplinary Breast Cancer Unit, Institut Català d'Oncologia, Idibell, Barcelona, Spain
Sonia Pernas Department of Medical Oncology, Multidisciplinary Breast Cancer Unit, Institut Català d'Oncologia, Idibell, Barcelona, Spain
Jordi Ponce Department of Gynecology, Multidisciplinary Breast Cancer Unit, Hospital Universitari Bellvitge, Idibell, c/ Feixa Llarga s/n. Hospitalet de Llobregat, CP: 08907, Barcelona, Spain
Amparo Garcia-Tejedor Department of Gynecology, Multidisciplinary Breast Cancer Unit, Hospital Universitari Bellvitge, Idibell, c/ Feixa Llarga s/n. Hospitalet de Llobregat, CP: 08907, Barcelona, Spain

Collapse

Falo C, Azcarate J, Fernandez-Gonzalez S, Perez X, Petit A, Perez H, Vethencourt A, Vazquez S, Laplana M, Ales M, Stradella A, Fullana B, Pla MJ, Gumà A, Ortega R, Varela M, Pérez D, Ponton JL, Cobo S, Benitez A, Campos M, Fernández A, Villanueva R, Obadia V, Recalde S, Soler-Monsó T, Lopez-Ojeda A, Martinez E, Ponce J, Pernas S, Gil-Gil M, Garcia-Tejedor A. Breast Cancer Patient's Outcomes after Neoadjuvant Chemotherapy and Surgery at 5 and 10 Years for Stage II-III Disease. Cancers (Basel) 2024;16:2421. [PMID: 39001483 PMCID: PMC11240707 DOI: 10.3390/cancers16132421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2024] [Revised: 06/24/2024] [Accepted: 06/26/2024] [Indexed: 07/16/2024] Open

Abstract

Introduction: Neoadjuvant chemotherapy in breast cancer offers the possibility to facilitate breast and axillary surgery; it is a test of chemosensibility in vivo with significant prognostic value and may be used to tailor adjuvant treatment according to the response. Material and Methods: A retrospective single-institution cohort of 482 stage II and III breast cancer patients treated with neoadjuvant chemotherapy based on anthracycline and taxans, plus antiHEr2 in Her2-positive cases, was studied. Survival was calculated at 5 and 10 years. Kaplan-Meier curves with a log-rank test were calculated for differences according to age, BRCA status, menopausal status, TNM, pathological and molecular surrogate subtype, 20% TIL cut-off, surgical procedure, response to chemotherapy and the presence of vascular invasion. Results: The pCR rate was 25.3% and was greater in HER2 (51.3%) and TNBC (31.7%) and in BRCA carriers (41.9%). The factors independently related to patient survival were pathology and molecular surrogate subtype, type of surgery, response to NACT and vascular invasion. BRCA status was a protective prognostic factor without reaching statistical significance, with an HR 0.5 (95%CI 0.1-1.4). Mastectomy presented a double risk of distant recurrence compared to breast-conservative surgery (BCS), supporting BCS as a safe option after NACT. After a mean follow-up of 126 (SD 43) months, luminal tumors presented a substantial difference in survival rates calculated at 5 or 10 years (81.2% compared to 74.7%), whereas that for TNBC was 75.3 and 73.5, respectively. The greatest difference was seen according to the response in patients with pCR, who exhibited a 10 years DDFS of 95.5% vs. 72.4% for those patients without pCR, p < 0001. This difference was especially meaningful in TNBC: the 10 years DDFS according to an RCB of 0 to 3 was 100%, 80.6%, 69% and 49.2%, respectively, p < 0001. Patients with a particularly poor prognosis were those with lobular carcinomas, with a 10 years DDFS of 42.9% vs. 79.7% for ductal carcinomas, p = 0.001, and patients with vascular invasion at the surgical specimen, with a 10 years DDFS of 59.2% vs. 83.6% for those patients without vascular invasion, p < 0.001. Remarkably, BRCA carriers presented a longer survival, with an estimated 10 years DDFS of 89.6% vs. 77.2% for non-carriers, p = 0.054. Conclusions: Long-term outcomes after neoadjuvant chemotherapy can help patients and clinicians make well-informed decisions.

Collapse

Affiliation(s)

Catalina Falo Multidisciplinary Breast Cancer Unit, Department of Medical Oncology, Institut Català d’Oncologia, 08908 Barcelona, Spain; (A.V.); (S.V.); (A.S.); (B.F.); (A.F.); (R.V.); (V.O.); (S.R.); (S.P.); (M.G.-G.) Instituto de Investigación Biomédica de Bellvitge (IDIBELL), 08908 Barcelona, Spain; (S.F.-G.); (A.P.); (H.P.); (M.L.); (M.J.P.); (A.G.); (R.O.); (M.V.); (E.M.); (J.P.); (A.G.-T.)
Juan Azcarate Multidisciplinary Breast Cancer Unit, Department of Pathology, Hospital Universitari Bellvitge, 08907 Barcelona, Spain; (J.A.); (T.S.-M.)
Sergi Fernandez-Gonzalez Instituto de Investigación Biomédica de Bellvitge (IDIBELL), 08908 Barcelona, Spain; (S.F.-G.); (A.P.); (H.P.); (M.L.); (M.J.P.); (A.G.); (R.O.); (M.V.); (E.M.); (J.P.); (A.G.-T.) Multidisciplinary Breast Cancer Unit, Department of Gynecology, Hospital Universitari Bellvitge, 08907 Barcelona, Spain;
Xavier Perez Information and Data Analysis Department, Institut Català d’Oncologia, Bellvitge Research Institute, 08908 Barcelona, Spain; (X.P.); (J.L.P.)
Ana Petit Instituto de Investigación Biomédica de Bellvitge (IDIBELL), 08908 Barcelona, Spain; (S.F.-G.); (A.P.); (H.P.); (M.L.); (M.J.P.); (A.G.); (R.O.); (M.V.); (E.M.); (J.P.); (A.G.-T.) Multidisciplinary Breast Cancer Unit, Department of Pathology, Hospital Universitari Bellvitge, 08907 Barcelona, Spain; (J.A.); (T.S.-M.)
Héctor Perez Instituto de Investigación Biomédica de Bellvitge (IDIBELL), 08908 Barcelona, Spain; (S.F.-G.); (A.P.); (H.P.); (M.L.); (M.J.P.); (A.G.); (R.O.); (M.V.); (E.M.); (J.P.); (A.G.-T.) Multidisciplinary Breast Cancer Unit, Department of Radiotherapy, Institut Català d’Oncologia, 08908 Barcelona, Spain
Andrea Vethencourt Multidisciplinary Breast Cancer Unit, Department of Medical Oncology, Institut Català d’Oncologia, 08908 Barcelona, Spain; (A.V.); (S.V.); (A.S.); (B.F.); (A.F.); (R.V.); (V.O.); (S.R.); (S.P.); (M.G.-G.) Instituto de Investigación Biomédica de Bellvitge (IDIBELL), 08908 Barcelona, Spain; (S.F.-G.); (A.P.); (H.P.); (M.L.); (M.J.P.); (A.G.); (R.O.); (M.V.); (E.M.); (J.P.); (A.G.-T.)
Silvia Vazquez Multidisciplinary Breast Cancer Unit, Department of Medical Oncology, Institut Català d’Oncologia, 08908 Barcelona, Spain; (A.V.); (S.V.); (A.S.); (B.F.); (A.F.); (R.V.); (V.O.); (S.R.); (S.P.); (M.G.-G.) Instituto de Investigación Biomédica de Bellvitge (IDIBELL), 08908 Barcelona, Spain; (S.F.-G.); (A.P.); (H.P.); (M.L.); (M.J.P.); (A.G.); (R.O.); (M.V.); (E.M.); (J.P.); (A.G.-T.)
Maria Laplana Instituto de Investigación Biomédica de Bellvitge (IDIBELL), 08908 Barcelona, Spain; (S.F.-G.); (A.P.); (H.P.); (M.L.); (M.J.P.); (A.G.); (R.O.); (M.V.); (E.M.); (J.P.); (A.G.-T.) Multidisciplinary Breast Cancer Unit, Department of Radiotherapy, Institut Català d’Oncologia, 08908 Barcelona, Spain
Miriam Ales Multidisciplinary Breast Cancer Unit, Department of Medical Oncology, Institut Català d’Oncologia, 08908 Barcelona, Spain; (A.V.); (S.V.); (A.S.); (B.F.); (A.F.); (R.V.); (V.O.); (S.R.); (S.P.); (M.G.-G.)
Agostina Stradella Multidisciplinary Breast Cancer Unit, Department of Medical Oncology, Institut Català d’Oncologia, 08908 Barcelona, Spain; (A.V.); (S.V.); (A.S.); (B.F.); (A.F.); (R.V.); (V.O.); (S.R.); (S.P.); (M.G.-G.) Instituto de Investigación Biomédica de Bellvitge (IDIBELL), 08908 Barcelona, Spain; (S.F.-G.); (A.P.); (H.P.); (M.L.); (M.J.P.); (A.G.); (R.O.); (M.V.); (E.M.); (J.P.); (A.G.-T.)
Bartomeu Fullana Multidisciplinary Breast Cancer Unit, Department of Medical Oncology, Institut Català d’Oncologia, 08908 Barcelona, Spain; (A.V.); (S.V.); (A.S.); (B.F.); (A.F.); (R.V.); (V.O.); (S.R.); (S.P.); (M.G.-G.) Instituto de Investigación Biomédica de Bellvitge (IDIBELL), 08908 Barcelona, Spain; (S.F.-G.); (A.P.); (H.P.); (M.L.); (M.J.P.); (A.G.); (R.O.); (M.V.); (E.M.); (J.P.); (A.G.-T.)
Maria J. Pla Instituto de Investigación Biomédica de Bellvitge (IDIBELL), 08908 Barcelona, Spain; (S.F.-G.); (A.P.); (H.P.); (M.L.); (M.J.P.); (A.G.); (R.O.); (M.V.); (E.M.); (J.P.); (A.G.-T.) Multidisciplinary Breast Cancer Unit, Department of Pathology, Hospital Universitari Bellvitge, 08907 Barcelona, Spain; (J.A.); (T.S.-M.)
Anna Gumà Instituto de Investigación Biomédica de Bellvitge (IDIBELL), 08908 Barcelona, Spain; (S.F.-G.); (A.P.); (H.P.); (M.L.); (M.J.P.); (A.G.); (R.O.); (M.V.); (E.M.); (J.P.); (A.G.-T.) Multidisciplinary Breast Cancer Unit, Department of Radiology, Hospital Universitari Bellvitge, 08907 Barcelona, Spain
Raul Ortega Instituto de Investigación Biomédica de Bellvitge (IDIBELL), 08908 Barcelona, Spain; (S.F.-G.); (A.P.); (H.P.); (M.L.); (M.J.P.); (A.G.); (R.O.); (M.V.); (E.M.); (J.P.); (A.G.-T.) Multidisciplinary Breast Cancer Unit, Department of Radiology, Hospital Universitari Bellvitge, 08907 Barcelona, Spain
Mar Varela Instituto de Investigación Biomédica de Bellvitge (IDIBELL), 08908 Barcelona, Spain; (S.F.-G.); (A.P.); (H.P.); (M.L.); (M.J.P.); (A.G.); (R.O.); (M.V.); (E.M.); (J.P.); (A.G.-T.) Multidisciplinary Breast Cancer Unit, Department of Pathology, Hospital Universitari Bellvitge, 08907 Barcelona, Spain; (J.A.); (T.S.-M.)
Diana Pérez Multidisciplinary Breast Cancer Unit, Department of Reparative Surgery, Hospital Universitari Bellvitge, 08907 Barcelona, Spain; (D.P.); (A.L.-O.)
Jose Luis Ponton Information and Data Analysis Department, Institut Català d’Oncologia, Bellvitge Research Institute, 08908 Barcelona, Spain; (X.P.); (J.L.P.)
Sara Cobo Multidisciplinary Breast Cancer Unit, Department of Pharmacy, Hospital Universitari Bellvitge, 08907 Barcelona, Spain;
Ana Benitez Multidisciplinary Breast Cancer Unit, Department of Nuclear Medicine, Hospital Universitari Bellvitge, 08907 Barcelona, Spain;
Miriam Campos Multidisciplinary Breast Cancer Unit, Department of Gynecology, Hospital Universitari Bellvitge, 08907 Barcelona, Spain;
Adela Fernández Multidisciplinary Breast Cancer Unit, Department of Medical Oncology, Institut Català d’Oncologia, 08908 Barcelona, Spain; (A.V.); (S.V.); (A.S.); (B.F.); (A.F.); (R.V.); (V.O.); (S.R.); (S.P.); (M.G.-G.) Instituto de Investigación Biomédica de Bellvitge (IDIBELL), 08908 Barcelona, Spain; (S.F.-G.); (A.P.); (H.P.); (M.L.); (M.J.P.); (A.G.); (R.O.); (M.V.); (E.M.); (J.P.); (A.G.-T.)
Rafael Villanueva Multidisciplinary Breast Cancer Unit, Department of Medical Oncology, Institut Català d’Oncologia, 08908 Barcelona, Spain; (A.V.); (S.V.); (A.S.); (B.F.); (A.F.); (R.V.); (V.O.); (S.R.); (S.P.); (M.G.-G.) Instituto de Investigación Biomédica de Bellvitge (IDIBELL), 08908 Barcelona, Spain; (S.F.-G.); (A.P.); (H.P.); (M.L.); (M.J.P.); (A.G.); (R.O.); (M.V.); (E.M.); (J.P.); (A.G.-T.)
Veronica Obadia Multidisciplinary Breast Cancer Unit, Department of Medical Oncology, Institut Català d’Oncologia, 08908 Barcelona, Spain; (A.V.); (S.V.); (A.S.); (B.F.); (A.F.); (R.V.); (V.O.); (S.R.); (S.P.); (M.G.-G.) Instituto de Investigación Biomédica de Bellvitge (IDIBELL), 08908 Barcelona, Spain; (S.F.-G.); (A.P.); (H.P.); (M.L.); (M.J.P.); (A.G.); (R.O.); (M.V.); (E.M.); (J.P.); (A.G.-T.)
Sabela Recalde Multidisciplinary Breast Cancer Unit, Department of Medical Oncology, Institut Català d’Oncologia, 08908 Barcelona, Spain; (A.V.); (S.V.); (A.S.); (B.F.); (A.F.); (R.V.); (V.O.); (S.R.); (S.P.); (M.G.-G.) Instituto de Investigación Biomédica de Bellvitge (IDIBELL), 08908 Barcelona, Spain; (S.F.-G.); (A.P.); (H.P.); (M.L.); (M.J.P.); (A.G.); (R.O.); (M.V.); (E.M.); (J.P.); (A.G.-T.)
Teresa Soler-Monsó Multidisciplinary Breast Cancer Unit, Department of Pathology, Hospital Universitari Bellvitge, 08907 Barcelona, Spain; (J.A.); (T.S.-M.)
Ana Lopez-Ojeda Multidisciplinary Breast Cancer Unit, Department of Reparative Surgery, Hospital Universitari Bellvitge, 08907 Barcelona, Spain; (D.P.); (A.L.-O.)
Evelyn Martinez Instituto de Investigación Biomédica de Bellvitge (IDIBELL), 08908 Barcelona, Spain; (S.F.-G.); (A.P.); (H.P.); (M.L.); (M.J.P.); (A.G.); (R.O.); (M.V.); (E.M.); (J.P.); (A.G.-T.) Multidisciplinary Breast Cancer Unit, Department of Radiotherapy, Institut Català d’Oncologia, 08908 Barcelona, Spain
Jordi Ponce Instituto de Investigación Biomédica de Bellvitge (IDIBELL), 08908 Barcelona, Spain; (S.F.-G.); (A.P.); (H.P.); (M.L.); (M.J.P.); (A.G.); (R.O.); (M.V.); (E.M.); (J.P.); (A.G.-T.) Multidisciplinary Breast Cancer Unit, Department of Gynecology, Hospital Universitari Bellvitge, 08907 Barcelona, Spain;
Sonia Pernas Multidisciplinary Breast Cancer Unit, Department of Medical Oncology, Institut Català d’Oncologia, 08908 Barcelona, Spain; (A.V.); (S.V.); (A.S.); (B.F.); (A.F.); (R.V.); (V.O.); (S.R.); (S.P.); (M.G.-G.) Instituto de Investigación Biomédica de Bellvitge (IDIBELL), 08908 Barcelona, Spain; (S.F.-G.); (A.P.); (H.P.); (M.L.); (M.J.P.); (A.G.); (R.O.); (M.V.); (E.M.); (J.P.); (A.G.-T.)
Miguel Gil-Gil Multidisciplinary Breast Cancer Unit, Department of Medical Oncology, Institut Català d’Oncologia, 08908 Barcelona, Spain; (A.V.); (S.V.); (A.S.); (B.F.); (A.F.); (R.V.); (V.O.); (S.R.); (S.P.); (M.G.-G.) Instituto de Investigación Biomédica de Bellvitge (IDIBELL), 08908 Barcelona, Spain; (S.F.-G.); (A.P.); (H.P.); (M.L.); (M.J.P.); (A.G.); (R.O.); (M.V.); (E.M.); (J.P.); (A.G.-T.)
Amparo Garcia-Tejedor Instituto de Investigación Biomédica de Bellvitge (IDIBELL), 08908 Barcelona, Spain; (S.F.-G.); (A.P.); (H.P.); (M.L.); (M.J.P.); (A.G.); (R.O.); (M.V.); (E.M.); (J.P.); (A.G.-T.) Multidisciplinary Breast Cancer Unit, Department of Pathology, Hospital Universitari Bellvitge, 08907 Barcelona, Spain; (J.A.); (T.S.-M.)

Collapse

Banys-Paluchowski M, Hartmann S, Ditsch N, Krawczyk N, Kühn T, de Boniface J, Banys-Kotomska J, Rody A, Krug D. Locoregional Therapy: From Mastectomy to Reconstruction, Targeted Surgery, and Ultra-Hypofractionated Radiotherapy. Breast Care (Basel) 2023;18:428-439. [PMID: 38130814 PMCID: PMC10731028 DOI: 10.1159/000533748] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2023] [Accepted: 08/21/2023] [Indexed: 12/23/2023] Open

Garcia-Tejedor A, Falo C, Fernandez-Gonzalez S, Laplana M, Gil-Gil M, Soler-Monso T, Martinez-Perez E, Calvo I, Calpelo H, Bajen MT, Benitez A, Ortega R, Petit A, Guma A, Campos M, Stradella A, Lopez-Ojeda A, Ponce J, Pla MJ, Pernas S. Management of the axilla in postmenopausal patients with cN0 hormone receptor-positive/HER2-negative breast cancer treated with neoadjuvant endocrine therapy and its prognostic impact. Breast Cancer Res Treat 2023;199:445-456. [PMID: 37043108 DOI: 10.1007/s10549-023-06926-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2022] [Accepted: 03/28/2023] [Indexed: 04/13/2023]

Affiliation(s)

Amparo Garcia-Tejedor Department of Gynaecology. Multidisciplinary, Breast Cancer Unit. Hospital Universitari Bellvitge, Idibell, Bellvitge Hospital, Ave. Feixa Llarga, sn Hospitalet de Llobregat, 08970, Barcelona, Spain.
Catalina Falo Department of Medical Oncology. Multidisciplinary Breast Cancer Unit, Institut Català d'Oncología, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
Sergi Fernandez-Gonzalez Department of Gynaecology. Multidisciplinary, Breast Cancer Unit. Hospital Universitari Bellvitge, Idibell, Bellvitge Hospital, Ave. Feixa Llarga, sn Hospitalet de Llobregat, 08970, Barcelona, Spain
Maria Laplana Department of Oncologic Radiotherapy. Multidisciplinary Breast Cancer Unit, Institut Català d'Oncología. IDIBELL, Barcelona, Spain
Miguel Gil-Gil Department of Medical Oncology. Multidisciplinary Breast Cancer Unit, Institut Català d'Oncología, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
Teresa Soler-Monso Department of Pathology. Multidisciplinary, Breast Cancer Unit. Hospital Universitari Bellvitge, Idibell, Barcelona, Spain
Evelyn Martinez-Perez Department of Oncologic Radiotherapy. Multidisciplinary Breast Cancer Unit, Institut Català d'Oncología. IDIBELL, Barcelona, Spain
Iris Calvo Department of Gynaecology. Multidisciplinary, Breast Cancer Unit. Hospital Universitari Bellvitge, Idibell, Bellvitge Hospital, Ave. Feixa Llarga, sn Hospitalet de Llobregat, 08970, Barcelona, Spain
Hugo Calpelo Department of Gynaecology. Multidisciplinary, Breast Cancer Unit. Hospital Universitari Bellvitge, Idibell, Bellvitge Hospital, Ave. Feixa Llarga, sn Hospitalet de Llobregat, 08970, Barcelona, Spain
Maria-Teresa Bajen Department of Nuclear Medicine, Multidisciplinary Breast Cancer Unit. Hospital Universitari Bellvitge, Idibell, Barcelona, Spain
Ana Benitez Department of Nuclear Medicine, Multidisciplinary Breast Cancer Unit. Hospital Universitari Bellvitge, Idibell, Barcelona, Spain
Raul Ortega Department of Radiology. Multidisciplinary, Breast Cancer Unit. Hospital Universitari Bellvitge, Idibell, Barcelona, Spain
Anna Petit Department of Pathology. Multidisciplinary, Breast Cancer Unit. Hospital Universitari Bellvitge, Idibell, Barcelona, Spain
Anna Guma Department of Radiology. Multidisciplinary, Breast Cancer Unit. Hospital Universitari Bellvitge, Idibell, Barcelona, Spain
Miriam Campos Department of Gynaecology. Multidisciplinary, Breast Cancer Unit. Hospital Universitari Bellvitge, Idibell, Bellvitge Hospital, Ave. Feixa Llarga, sn Hospitalet de Llobregat, 08970, Barcelona, Spain
Agostina Stradella Department of Medical Oncology. Multidisciplinary Breast Cancer Unit, Institut Català d'Oncología, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
Ana Lopez-Ojeda Department of Plastic Surgery. Multidisciplinary, Breast Cancer Unit. Hospital Universitari Bellvitge, Idibell, Barcelona, Spain
Jordi Ponce Department of Gynaecology. Multidisciplinary, Breast Cancer Unit. Hospital Universitari Bellvitge, Idibell, Bellvitge Hospital, Ave. Feixa Llarga, sn Hospitalet de Llobregat, 08970, Barcelona, Spain
Maria J Pla Department of Gynaecology. Multidisciplinary, Breast Cancer Unit. Hospital Universitari Bellvitge, Idibell, Bellvitge Hospital, Ave. Feixa Llarga, sn Hospitalet de Llobregat, 08970, Barcelona, Spain
Sonia Pernas Department of Medical Oncology. Multidisciplinary Breast Cancer Unit, Institut Català d'Oncología, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.

Collapse

Friedrich M, Kühn T, Janni W, Müller V, Banys-Pachulowski M, Kolberg-Liedtke C, Jackisch C, Krug D, Albert US, Bauerfeind I, Blohmer J, Budach W, Dall P, Fallenberg EM, Fasching PA, Fehm T, Gerber B, Gluz O, Hanf V, Harbeck N, Heil J, Huober J, Kreipe HH, Kümmel S, Loibl S, Lüftner D, Lux MP, Maass N, Möbus V, Mundhenke C, Nitz U, Park-Simon TW, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn HP, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Thill M, Ditsch N. AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update. Geburtshilfe Frauenheilkd 2021;81:1112-1120. [PMID: 34629490 PMCID: PMC8494519 DOI: 10.1055/a-1499-8431] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2021] [Accepted: 05/04/2021] [Indexed: 12/16/2022] Open

Affiliation(s)

Michael Friedrich Klinik für Frauenheilkunde und Geburtshilfe, HELIOS Klinikum Krefeld, Krefeld, Germany
Thorsten Kühn Gynäkologie, Klinikum Esslingen, Esslingen, Germany
Wolfgang Janni Frauenklinik, Klinikum der Universität Ulm, Ulm, Germany
Volkmar Müller Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
Maggie Banys-Pachulowski Klinik für Frauenheilkunde und Geburtshilfe, UK-SH, Lübeck, Germany.,Medizinische Fakultät, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany
Cornelia Kolberg-Liedtke Klinik für Gynäkologie mit Brustzentrum des Universitätsklinikums der Charité, Berlin, Germany
Christian Jackisch Klinik für Gynäkologie und Geburtshilfe, Sana Klinikum Offenbach, Offenbach, Germany
David Krug Universitätsklinikum Schleswig-Holstein, Klinik für Strahlentherapie, Campus Kiel, Kiel, Germany
Ute-Susann Albert Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Würzburg, Würzburg, Germany
Ingo Bauerfeind Frauenklinik, Klinikum Landshut gemeinnützige GmbH, Landshut, Germany
Jens Blohmer Klinik für Gynäkologie mit Brustzentrum des Universitätsklinikums der Charité, Berlin, Germany
Wilfried Budach Strahlentherapie, Radiologie Düsseldorf, Universitätsklinikum Düsseldorf, Düsseldorf, Germany
Peter Dall Frauenklinik, Städtisches Klinikum Lüneburg, Lüneburg, Germany
Eva M Fallenberg Klinikum der Universität München, Campus Großhadern, Institut für Klinische Radiologie, München, Germany
Peter A Fasching Universitätsklinikum Erlangen, Frauenklinik, Erlangen, Germany
Tanja Fehm Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Düsseldorf, Düsseldorf, Germany
Bernd Gerber Universitätsfrauenklinik am Klinikum Südstadt, Klinikum Südstadt Rostock, Rostock, Germany
Oleg Gluz Evangelisches Krankenhaus Bethesda, Brustzentrum, Mönchengladbach, Germany
Volker Hanf Frauenklinik, Nathanstift Klinikum Fürth, Fürth, Germany
Nadia Harbeck Brustzentrum, Klinik für Gynäkologie und Geburtshilfe, Klinikum der Ludwig-Maximilians-Universität, München, Germany
Jörg Heil Universitäts-Klinikum Heidelberg, Brustzentrum, Heidelberg, Germany
Jens Huober Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Ulm, Ulm, Germany
Hans-Heinrich Kreipe Institut für Pathologie, Medizinische Hochschule Hannover, Hannover, Germany
Sherko Kümmel Evangelische Kliniken Essen Mitte, Essen, Germany
Sibylle Loibl German Breast Group Forschungs GmbH, Neu-Isenburg, Germany
Diana Lüftner Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie, Charité, Berlin, Germany
Michael Patrick Lux Kooperatives Brustzentrum Paderborn, Klinik für Gynäkologie und Geburtshilfe, Frauenklinik, St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, St. Vincenz Krankenhaus GmbH, Germany
Nicolai Maass Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany
Volker Möbus Klinik für Gynäkologie und Geburtshilfe, Klinikum Frankfurt Höchst GmbH, Frankfurt am Main, Germany
Christoph Mundhenke Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany
Ulrike Nitz Evangelisches Krankenhaus Bethesda, Brustzentrum, Mönchengladbach, Germany
Tjoung-Won Park-Simon Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Hannover, Hannover, Germany
Toralf Reimer Universitätsfrauenklinik am Klinikum Südstadt, Klinikum Südstadt Rostock, Rostock, Germany
Kerstin Rhiem Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum Köln, Köln, Germany
Achim Rody Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Germany
Marcus Schmidt Klinik und Poliklinik für Geburtshilfe und Frauengesundheit der Johannes-Gutenberg-Universität Mainz, Mainz, Germany
Andreas Schneeweiss Universitäts-Klinikum Heidelberg, Brustzentrum, Heidelberg, Germany
Florian Schütz Klinik für Gynäkologie und Geburtshilfe, Diakonissen Krankenhaus Speyer, Speyer, Germany
Hans-Peter Sinn Sektion Gynäkopathologie, Pathologisches Institut, Universitätsklinikum Heidelberg, Heidelberg, Germany
Christine Solbach Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Frankfurt, Frankfurt am Main, Germany
Erich-Franz Solomayer Klinik für Frauenheilkunde, Geburtshilfe und Reproduktionsmedizin, Universitätsklinikum des Saarlandes, Homburg, Germany
Elmar Stickeler Klinik für Gynäkologie und Geburtsmedizin, Universitätsklinikum Aachen, Aachen, Germany
Christoph Thomssen Universitätsfrauenklinik, Martin-Luther-Universität Halle-Wittenberg, Halle-Wittenberg, Germany
Michael Untch Klinik für Gynäkologie und Geburtshilfe, Helios Klinikum Berlin-Buch, Berlin, Germany
Isabell Witzel Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
Achim Wöckel Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Würzburg, Würzburg, Germany
Marc Thill Klinik für Gynäkologie und Gynäkologische Onkologie, Agaplesion Markus Krankenhaus, Frankfurt am Main, Germany
Nina Ditsch Frauenklinik, Universitätsklinikum Augsburg, Augsburg, Germany

Collapse

Hossain S, Hossain S. Mathematical and computational modeling for the determination of optical parameters of breast cancer cell. Electromagn Biol Med 2021;40:447-458. [PMID: 34323633 DOI: 10.1080/15368378.2021.1958339] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]

Brackstone M, Baldassarre FG, Perera FE, Cil T, Chavez Mac Gregor M, Dayes IS, Engel J, Horton JK, King TA, Kornecki A, George R, SenGupta SK, Spears PA, Eisen AF. Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline. J Clin Oncol 2021;39:3056-3082. [PMID: 34279999 DOI: 10.1200/jco.21.00934] [Citation(s) in RCA: 95] [Impact Index Per Article: 31.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open

Fernandez-Gonzalez S, Falo C, Pla MJ, Verdaguer P, Nuñez D, Guma A, Soler T, Vethencourt A, Vázquez S, Fernandez-Montoli ME, Campos M, Pernas S, Gil M, Ponce J, Garcia-Tejedor A. Predictive factors for omitting lymphadenectomy in patients with node-positive breast cancer treated with neo-adjuvant systemic therapy. Breast J 2020;26:888-896. [PMID: 32052521 DOI: 10.1111/tbj.13763] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2019] [Revised: 01/09/2020] [Accepted: 01/10/2020] [Indexed: 12/17/2022]

Affiliation(s)

Sergi Fernandez-Gonzalez Multidisciplinary Breast Cancer Unit, Department of Gynecology, Hospital Universitari Bellvitge, Idibell, Barcelona, Spain
Catalina Falo Multidisciplinary Breast Cancer Unit, Department of Oncology, Institut Català d'Oncología, Barcelona, Spain
Maria J Pla Multidisciplinary Breast Cancer Unit, Department of Gynecology, Hospital Universitari Bellvitge, Idibell, Barcelona, Spain
Paula Verdaguer Multidisciplinary Breast Cancer Unit, Department of Gynecology, Hospital Universitari Bellvitge, Idibell, Barcelona, Spain
Diana Nuñez Multidisciplinary Breast Cancer Unit, Department of Gynecology, Hospital Universitari Bellvitge, Idibell, Barcelona, Spain
Anna Guma Multidisciplinary Breast Cancer Unit, Department of Radiology, Hospital Universitari Bellvitge, Idibell, Barcelona, Spain
Teresa Soler Multidisciplinary Breast Cancer Unit, Department of Pathology, Hospital Universitari Bellvitge, Idibell, Barcelona, Spain
Andrea Vethencourt Multidisciplinary Breast Cancer Unit, Department of Oncology, Institut Català d'Oncología, Barcelona, Spain
Silvia Vázquez Multidisciplinary Breast Cancer Unit, Department of Gynecology, Hospital Universitari Bellvitge, Idibell, Barcelona, Spain
Maria Eulalia Fernandez-Montoli Multidisciplinary Breast Cancer Unit, Department of Gynecology, Hospital Universitari Bellvitge, Idibell, Barcelona, Spain
Miriam Campos Multidisciplinary Breast Cancer Unit, Department of Gynecology, Hospital Universitari Bellvitge, Idibell, Barcelona, Spain
Sonia Pernas Multidisciplinary Breast Cancer Unit, Department of Oncology, Institut Català d'Oncología, Barcelona, Spain
Miguel Gil Multidisciplinary Breast Cancer Unit, Department of Oncology, Institut Català d'Oncología, Barcelona, Spain
Jordi Ponce Multidisciplinary Breast Cancer Unit, Department of Gynecology, Hospital Universitari Bellvitge, Idibell, Barcelona, Spain
Amparo Garcia-Tejedor Multidisciplinary Breast Cancer Unit, Department of Gynecology, Hospital Universitari Bellvitge, Idibell, Barcelona, Spain

Collapse

Moustafa AFI, Kamal RM, Gomaa MMM, Mostafa S, Mubarak R, El-Adawy M. Quantitative mathematical objective evaluation of contrast-enhanced spectral mammogram in the assessment of response to neoadjuvant chemotherapy and prediction of residual disease in breast cancer. THE EGYPTIAN JOURNAL OF RADIOLOGY AND NUCLEAR MEDICINE 2019. [DOI: 10.1186/s43055-019-0041-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open

Abstract Abstract Background The aim of the study is to initiate a new quantitative mathematical objective tool for evaluation of response to neoadjuvant chemotherapy (NAC) and prediction of residual disease in breast cancer using contrast-enhanced spectral mammography (CESM). Forty-two breast cancer patients scheduled for receiving NAC were included. All patients underwent two CESM examinations: pre and post NAC. To assess the response to neoadjuvant chemotherapy, we used a mathematical image analysis software that can calculate the difference in the intensity of enhancement between the pre and post neoadjuvant contrast images (MATLAB and Simulink) (Release 2013b). The proposed technique used the pre and post neoadjuvant contrast images as inputs. The technique consists of three main steps: (1) preprocessing, (2) extracting the region of interest (ROI), and (3) assessment of the response to chemotherapy by measuring the percentage of change in the intensity of enhancement of malignant lesions in the pre and post neoadjuvant CESM studies using a quantitative mathematical technique. This technique depends on the analysis of number of pixels included within the ROI. We compared this technique with the currently used method of evaluation: RECIST 1.1 (response evaluation criteria in solid tumors 1.1) and using another combined response evaluation approach using both RECIST 1.1 in addition to a subjective visual evaluation. Results were then correlated with the postoperative pathology evaluation using Miller–Payne grades. For statistical evaluation, patients were classified into responders and non-responders in all evaluation methods. Results According to the Miller–Payne criteria, 39/42 (92.9%) of the participants were responders (Miller–Payne grades III, IV, and IV) and 3/42 (7.1%) were non-responders (Miller–Payne grades I and II). Using the proposed technique, 39/39 (100%) were responders in comparison to 38/39 patients (97.4%) using the combined criteria and 34/39 (87.2%) using the RECIST 1.1 evaluation. The calculated correlation coefficient of the proposed quantitative objective mathematical technique, RECIST 1.1 criteria, and the combined method was 0.89, 0.59, and 0.69 respectively. With classification of patients into responder and non-responders, the objective mathematical evaluation showed higher sensitivity, positive and negative predictive values, and overall accuracy (100%, 97.5%, 100%, and 85.7% respectively) compared to RECIST 1.1 evaluation (87.2%, 97.1%, 28.6%, and 54.8% respectively) and the combined response method (97.4%, 97.4%, 66.7%, and 85.7% respectively). Conclusion Quantitative mathematical objective evaluation using CESM images allows objective quantitative and accurate evaluation of the response of breast cancer to chemotherapy and is recommended as an alternative to the subjective techniques as a part of the pre-operative workup. Collapse

Schütz F, Fasching PA, Welslau M, Hartkopf AD, Wöckel A, Lux MP, Janni W, Ettl J, Lüftner D, Belleville E, Kolberg HC, Overkamp F, Taran FA, Brucker SY, Wallwiener M, Tesch H, Fehm TN, Schneeweiss A, Müller V. Update Breast Cancer 2019 Part 4 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer. Geburtshilfe Frauenheilkd 2019;79:1079-1089. [PMID: 31656318 PMCID: PMC6805214 DOI: 10.1055/a-1001-9925] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2019] [Revised: 08/04/2019] [Accepted: 08/22/2019] [Indexed: 02/06/2023] Open

Affiliation(s)

Florian Schütz Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany
Peter A. Fasching Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
Manfred Welslau Onkologie Aschaffenburg, Aschaffenburg, Germany
Andreas D. Hartkopf Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany
Achim Wöckel Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany
Michael P. Lux Kooperatives Brustzentrum Paderborn, Klinik für Gynäkologie und Geburtshilfe Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, Germany
Wolfgang Janni Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
Johannes Ettl Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
Diana Lüftner Charité University Hospital, Campus Benjamin Franklin, Department of Hematology, Oncology and Tumour Immunology, Berlin, Germany
Erik Belleville ClinSol GmbH & Co KG, Würzburg, Germany
Hans-Christian Kolberg Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany
Friedrich Overkamp OncoConsult Hamburg GmbH, Hamburg, Germany
Florin-Andrei Taran Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany
Sara Y. Brucker Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany
Markus Wallwiener Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany
Hans Tesch Oncology Practice at Bethanien Hospital Frankfurt, Frankfurt, Germany
Tanja N. Fehm Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany
Andreas Schneeweiss National Center for Tumor Diseases, Division Gynecologic Oncology, University Hospital Heidelberg, Heidelberg, Germany
Volkmar Müller Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany

Collapse

Hartkopf AD, Müller V, Wöckel A, Lux MP, Janni W, Nabieva N, Taran FA, Ettl J, Lüftner D, Belleville E, Schütz F, Fasching PA, Fehm TN, Kolberg HC, Overkamp F, Schneeweiss A, Tesch H. Update Breast Cancer 2019 Part 1 - Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer. Geburtshilfe Frauenheilkd 2019;79:256-267. [PMID: 30880824 PMCID: PMC6414304 DOI: 10.1055/a-0842-6614] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2019] [Accepted: 01/28/2019] [Indexed: 12/18/2022] Open

Affiliation(s)

Andreas D. Hartkopf Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany
Volkmar Müller Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany
Achim Wöckel Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany
Michael P. Lux Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
Wolfgang Janni Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
Naiba Nabieva Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
Florin-Andrei Taran Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany
Johannes Ettl Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
Diana Lüftner Charité University Hospital, Campus Benjamin Franklin, Department of Hematology, Oncology and Tumour Immunology, Berlin, Germany
Erik Belleville ClinSol GmbH & Co. KG, Würzburg, Germany
Florian Schütz Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany
Peter A. Fasching Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
Tanja N. Fehm Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany
Hans-Christian Kolberg Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany
Friedrich Overkamp OncoConsult Hamburg GmbH, Hamburg, Germany
Andreas Schneeweiss National Center for Tumor Diseases, Division Gynecologic Oncology, University Hospital Heidelberg, Heidelberg, Germany
Hans Tesch Oncology Practice at Bethanien Hospital Frankfurt, Frankfurt, Germany

Collapse

Kantor O, Pesce C, Liederbach E, Wang CH, Winchester DJ, Yao K. Author's response. Breast J 2018;24:1143. [PMID: 30051547 DOI: 10.1111/tbj.13105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2018] [Accepted: 05/09/2018] [Indexed: 11/30/2022]

Desai AA, Hoskin TL, Day CN, Habermann EB, Boughey JC. Effect of Primary Breast Tumor Location on Axillary Nodal Positivity. Ann Surg Oncol 2018;25:3011-3018. [PMID: 29968027 DOI: 10.1245/s10434-018-6590-7] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2018] [Indexed: 01/09/2023]